Relay Therapeutics, Inc. (RLAY): who owns it and who trades it
As of Nov 16, 2026, RLAY insiders reported 39 open-market sales worth $129M and no purchases in the last 12 months, with 1% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sb Investment Advisers (Uk) Ltd (10% owner), with $116M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Relay Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RLAY
259 funds and institutions reported RLAY shares worth $4.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Sb Investment Advisers (uk) Ltd with 14.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Sb Investment Advisers (uk) Ltd | 27.90M | 14.57% | $522M | No change |
| FMR LLC (Fidelity) | 20.11M | 10.50% | $376M | +444% |
| Casdin Capital, LLC | 16.04M | 8.37% | $300M | +11% |
| BlackRock, Inc. | 15.29M | 7.98% | $286M | +18% |
| Perceptive Advisors LLC | 14.11M | 7.36% | $264M | +45% |
| Commodore Capital LP | 12.00M | 6.26% | $225M | -29% |
| State Street Corp | 10.13M | 5.29% | $189M | +62% |
| Vanguard Capital Management LLC | 8.96M | 4.68% | $168M | +21% |
| T. Rowe Price Associates | 7.71M | 4.02% | $144M | +300% |
| Nextech Invest Ltd. | 6.78M | 3.54% | $127M | +23% |
| Bellevue Group AG | 6.19M | 3.23% | $116M | -21% |
| Geode Capital Management, LLC | 4.73M | 2.47% | $88.4M | +35% |
| TCG Crossover Management, LLC | 4.27M | 2.23% | $80M | No change |
| Alliancebernstein L.P. | 4.10M | 2.14% | $40.8M | +2720% |
| Morgan Stanley | 3.85M | 2.01% | $72.1M | +169% |
| Siren, L.L.C. | 3.65M | 1.91% | $68.3M | – |
| Goldman Sachs Group Inc | 3.41M | 1.78% | $63.8M | +34% |
| Westfield Capital Management Co LP | 3.34M | 1.75% | $62.6M | – |
| Kynam Capital Management, LP | 3.30M | 1.72% | $61.7M | +132% |
| California State Teachers Retirement System | 3.18M | 1.66% | $170M | +1726% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RLAY insiders reported $0 of open-market purchases and $129M of sales. 1% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | Donald A Bergstrom | President | Sale | 2,252 | $18.62 | $41.9K | Form 4 |
| Oct 28, 2026 | Thomas Catinazzo | CFO | Sale | 1,469 | $18.62 | $27.4K | Form 4 |
| Oct 28, 2026 | Peter Rahmer | See remarks | Sale | 753 | $18.62 | $14K | Form 4 |
| Oct 7, 2026 | Sanjiv Patel | CEO | Sale plan | 48,199 | $18.10 | $872K | Form 4 |
| Oct 6, 2026 | Thomas Catinazzo | CFO | Sale plan | 17,511 | $18.58 | $325K | Form 4 |
| Oct 6, 2026 | Thomas Catinazzo | CFO | Sale plan | 206 | $19.26 | $4K | Form 4 |
| Sep 8, 2026 | Donald A Bergstrom | President | Sale | 8,530 | $18.97 | $162K | Form 4 |
| Sep 8, 2026 | Thomas Catinazzo | CFO | Sale | 17,717 | $18.94 | $336K | Form 4 |
| Sep 8, 2026 | Sanjiv Patel | CEO | Sale | 48,199 | $18.94 | $913K | Form 4 |
| Aug 26, 2026 | Peter Rahmer | See remarks | Sale | 4,508 | $20.03 | $90.3K | Form 4 |
| Aug 25, 2026 | Sb Investment Advisers (Uk) Ltd +2 | 10% owner | Sale | 6.00M | $19.40 | $116M | Form 4 |
| Aug 17, 2026 | Sanjiv Patel | CEO | Sale | 48,199 | $20.33 | $980K | Form 4 |
| Aug 14, 2026 | Thomas Catinazzo | CFO | Sale | 17,717 | $19.74 | $350K | Form 4 |
| Jul 28, 2026 | Thomas Catinazzo | CFO | Sale | 1,459 | $18.61 | $27.2K | Form 4 |
| Jul 28, 2026 | Peter Rahmer | See remarks | Sale | 748 | $18.61 | $13.9K | Form 4 |
| Jul 28, 2026 | Donald A Bergstrom | President | Sale | 2,237 | $18.61 | $41.6K | Form 4 |
| Jul 7, 2026 | Sanjiv Patel | CEO | Sale | 48,199 | $19.58 | $944K | Form 4 |
| Jul 6, 2026 | Donald A Bergstrom | President | Sale | 8,660 | $18.71 | $162K | Form 4 |
| Jul 6, 2026 | Thomas Catinazzo | CFO | Sale | 17,717 | $18.69 | $331K | Form 4 |
| Jun 30, 2026 | Peter Rahmer | See remarks | Sale | 50,000 | $19.09 | $954K | Form 4 |
| Jun 22, 2026 | Thomas Catinazzo | CFO | Sale | 56,323 | $16.97 | $956K | Form 4 |
| Jun 22, 2026 | Thomas Catinazzo | CFO | Sale | 61,563 | $16.97 | $1M | Form 4 |
| Jun 22, 2026 | Thomas Catinazzo | CFO | Sale | 51,560 | $16.97 | $875K | Form 4 |
| Jun 22, 2026 | Thomas Catinazzo | CFO | Sale | 17,717 | $17.01 | $301K | Form 4 |
| Jun 22, 2026 | Donald A Bergstrom | President | Sale | 93,456 | $16.94 | $1.6M | Form 4 |
| May 14, 2026 | Thomas Catinazzo | CFO | Sale | 17,717 | $12.86 | $228K | Form 4 |
| Apr 28, 2026 | Thomas Catinazzo | CFO | Sale | 972 | $14.79 | $14.4K | Form 4 |
| Apr 28, 2026 | Peter Rahmer | See remarks | Sale | 753 | $14.79 | $11.1K | Form 4 |
| Apr 28, 2026 | Donald A Bergstrom | President | Sale | 1,490 | $14.79 | $22K | Form 4 |
| Apr 9, 2026 | Thomas Catinazzo | CFO | Sale | 1,800 | $15.00 | $27K | Form 4 |
| Apr 7, 2026 | Thomas Catinazzo | CFO | Sale | 17,717 | $13.01 | $230K | Form 4 |
| Mar 9, 2026 | Thomas Catinazzo | CFO | Sale | 17,717 | $10.06 | $178K | Form 4 |
| Jan 28, 2026 | Donald A Bergstrom | President | Sale | 2,686 | $8.45 | $22.7K | Form 4 |
| Jan 28, 2026 | Peter Rahmer | See remarks | Sale | 1,354 | $8.45 | $11.4K | Form 4 |
| Jan 28, 2026 | Thomas Catinazzo | CFO | Sale | 1,695 | $8.45 | $14.3K | Form 4 |
| Jan 27, 2026 | Donald A Bergstrom | President | Sale | 18,895 | $7.62 | $144K | Form 4 |
| Jan 27, 2026 | Peter Rahmer | See remarks | Sale | 11,684 | $7.62 | $89K | Form 4 |
| Jan 27, 2026 | Thomas Catinazzo | CFO | Sale | 13,820 | $7.62 | $105K | Form 4 |
| Jan 6, 2026 | Sanjiv Patel | CEO | Sale | 43,168 | $7.82 | $338K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Sb Investment Advisers (Uk) Ltd | 10% owner | – | $116M | Aug 25, 2026 |
| Thomas Catinazzo | Chief Financial Officer | – | $5.4M | Oct 28, 2026 |
| Sanjiv Patel | President and CEO, Director | – | $4M | Oct 7, 2026 |
| Donald A Bergstrom | President, R&D | – | $2.2M | Oct 28, 2026 |
| Peter Rahmer | See remarks | – | $1.2M | Oct 28, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RLAY short interest
High short interest. 19.7% of RLAY shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 51%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 43.63M RLAY shares were sold short, 19.7% of the shares outstanding, down 0.9% from the report before. At the average daily volume of 2.11M shares, buying them all back would take about 20.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 43.63M | 19.75% | -1% | 2.11M | 20.7 |
| Oct 15, 2026 | 44.03M | 20.09% | -6% | 2.75M | 16.0 |
| Sep 30, 2026 | 46.75M | 21.33% | +5% | 3.71M | 12.6 |
| Sep 15, 2026 | 44.49M | 20.30% | +2% | 3.13M | 14.2 |
| Aug 31, 2026 | 43.55M | 19.87% | +5% | 2.60M | 16.7 |
| Aug 14, 2026 | 41.36M | 18.87% | +3% | 1.92M | 21.6 |
| Jul 31, 2026 | 40.25M | 18.37% | -5% | 2.31M | 17.4 |
| Jul 15, 2026 | 42.56M | 22.21% | -1% | 3.18M | 13.4 |
| Jun 30, 2026 | 43.04M | 22.47% | +13% | 5.95M | 7.2 |
| Jun 15, 2026 | 38.12M | 19.90% | +11% | 3.87M | 9.8 |
| May 29, 2026 | 34.39M | 17.95% | +19% | 5.99M | 5.7 |
| May 15, 2026 | 28.82M | 15.04% | +5% | 2.80M | 10.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Relay Therapeutics company events
Relay Therapeutics filed 11 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 6, 2026AgreementRelay Therapeutics, Inc. previously entered into a common stock sales agreement, dated August 6, 2024, with TD Securities (USA) LLC, relating to shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $250 million, through TD Cowen. Filing
- Jun 9, 2026VoteReported shareholder vote results. Filing
- May 21, 2026AgreementRelay Therapeutics, Inc. entered into an Underwriting Agreement with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto, relating to an underwritten public offering of 22,916,667 shares of the Company’s common stock, $0.001 par… Filing
- May 19, 2026AnnouncementThe Company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 27, 2026AnnouncementThe Company announced clinical data from the zovegalisib, fulvestrant and atirmociclib triplet combination arm of the Phase 1/2 ReDiscover trial as well as the Company's plans to move zovegalisib plus atirmociclib into Phase 3 development for 1L patients with PI3Kα-mutated, HR+/HER2- metastatic… Filing
- Mar 16, 2026AnnouncementThe Company announced data from the Phase 1/2 ReDiscover trial of zovegalisib in combination with fulvestrant at the 400mg BID fed dose, which is the recommended Phase 3 dose, at the European Society for Medical Oncology Targeted Anticancer Therapies Congress 2026. Filing
- Mar 11, 2026RulesChanged its bylaws or articles. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Feb 3, 2026AnnouncementThe Company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Relay Therapeutics financials
Famous investors that hold RLAY
3 of the 50 well-known investors we track reported holding RLAY in their latest 13F filing. The largest position is Stanley Druckenmiller's, worth $15.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 852,600 | $15.4M | 0.4% | +144% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 78,755 | $1.4M | 0.0% | -83% |
| Israel Englander · Millennium Management | Q3 2026 | 14,217 | $257K | 0.0% | -98% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named RLAY in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G | 8.2% |
| Nov 16, 2026 | T. Rowe Price Investment Management, Inc. | 13G | 8.2% |
| Nov 16, 2026 | SB Investment Advisers (UK) Limited | 13G/A | 9.9% |
| Nov 16, 2026 | SB Investment Advisers (UK) Limited | 13G/A | 9.9% |
Questions about Relay Therapeutics, Inc. (RLAY) stock
Who owns the most RLAY stock?
The largest reported owner of Relay Therapeutics, Inc. (RLAY) is Sb Investment Advisers (uk) Ltd, with 14.6% of the company. In total, 259 funds and institutions reported holding RLAY at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are RLAY insiders buying or selling?
In the last 12 months, RLAY insiders reported no open-market purchases and 39 sales worth $129M. The latest trade was on Oct 28, 2026. See every trade.
What is the short interest in RLAY?
As of Oct 30, 2026, 43.63M RLAY shares were sold short, 19.7% of the shares outstanding, down 0.9% from the report before. At the average daily volume of 2.11M shares, buying them all back would take about 20.7 trading days (days to cover). See the history.
Which famous investors hold RLAY?
3 of the 50 well-known investors we track reported RLAY in their latest 13F filing, including Stanley Druckenmiller, Ken Griffin, Israel Englander. The largest position is worth $15.4M. See all holders.
Executive pay
Relay Therapeutics's chief executive was paid a total of $4.6M for the year ended Dec 31, 2025, down 64% from $13.1M the year before. In the last 12 months, Relay Therapeutics's executives and directors bought no stock on the open market and sold $12.8M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.